SOURCE: Symmetry Technologies, Inc.

October 10, 2007 11:29 ET

Symmetry Technologies, Inc. Prepares for Bright Future

HOUSTON, TX--(Marketwire - October 10, 2007) - Symmetry Technologies, Inc. (PINKSHEETS: SMMR) is isolating compounds that, it believes, will induce apoptosis in senescent cells, stimulate stem cell growth, and suppress herpes activity. The Company believes that by clearing tissues with short average telomere length and stimulating longer telomere cell growth, including differentiation from stem cell populations, while ameliorating the effects of HSV activity, they will produce an effect that is tantamount to cell rejuvenation. Symmetry is accomplishing these biological tasks using compounds that have been accepted as safe for human consumption and already approved for human use, believing that the "art" will be in producing the desired effect using combinations of such compounds. "The process of creating this product has been very interesting," said President Chad Reed. "This is the first of many products we hope to bring to the marketplace." The Company's research in this area is being pursued in cooperation with Quantum Bit Induction Technology, Inc. ( and a small group of Ph.D. biologists.

Symmetry operates, which is a US online pharmacy. The Company carries a variety of products and is planning to add this proprietary combinatorial rejuvenation therapy to the product library in the future. RapidScripts is an easy-access pharmacy with quality products priced very competitively.

This release contains statements that are based on the best judgment of the Company. The Company cautions all interested investors that many uncertainties exist and thorough due diligence should be undertaken by any person prior to making an investment decision. Anyone interested in the Company is invited to communicate with management through email which can be found on our corporate website

Contact Information